Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

oche through a global development and commercialization agreement.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the Company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements related to the further development and potential safety, efficacy, commercialization and other characteristics of tanespimycin, Kosan's development plans with respect to tanespimycin, including but not limited to Kosan's plans and timing for the initiation of the TIME-1 trial and TIME-2 as a potential registration trial, and the FDA's later review of the results of the TIME-1 clinical trial. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward- looking statements, including, among others, risks related to the development of tanespimycin, including the risk that studies and ongoing trials may not demonstrate safety and efficacy sufficient to initiate additional clinical trials, continue clinical development on the timing currently anticipated or at all, obtain the requisite regulatory approvals or result in a marketable product; risks related to regulatory requirements and other risks detailed from time to time in the Kosan's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward- looking statements.

'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Pharmaceutical and ... managing multiple products for the same indication. This can ... that want to prevent one of their brands from ... According to recent research by benchmarking firm, Best ... as independent brands rather than together as part of ...
(Date:2/27/2015)... 2015  Acsis Inc., the market leader for supply ... that John DiPalo , Acsis, Chief Strategy Officer, ... Chain Executive 2015 Provider Pro to Know. The ... to help prepare their companies, and customers, supply chains ... year,s list of Provider Pros to Know is featured ...
(Date:2/27/2015)... VANCOUVER, Canada and HOUSTON, TX ... ("ESSA" or the "Company") (TSX-V: EPI) and Bloom Burton ... have released from voluntary contractual lock-up (the "Lock-Up") 2,353,130 ... of the Common Shares originally subject to the Lock-Up. ... shares will be free trading immediately upon release from ...
Breaking Medicine Technology:New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4
... May 5, 2011 Cardiac Network, Inc. (Other OTC: CNWI.PK) ... 1-for-750 reverse stock split (the "Reverse Stock Split"). The Reverse ... and trading on May 6, 2011 (the "Effective Date"). On ... from "CNWI" to "CNWID" for approximately 20 business days, after ...
... ARAY ), a global leader in the field ... of fiscal year 2011, ended March 31, 2011. ... total revenue of $54.7 million, an increase of five percent ... of fiscal 2010. Total revenue during the third quarter of ...
Cached Medicine Technology:Cardiac Network Announces Reverse Stock Split 2Accuray Announces Results for Third Quarter of Fiscal 2011 2Accuray Announces Results for Third Quarter of Fiscal 2011 3Accuray Announces Results for Third Quarter of Fiscal 2011 4Accuray Announces Results for Third Quarter of Fiscal 2011 5Accuray Announces Results for Third Quarter of Fiscal 2011 6
(Date:2/28/2015)... The noted Friedman Dental Group of South ... relaunched their website. The new version of the site ... new section about their team members. Potential and current ... of each Friedman Dental Group team member including new ... to provide our patients with the opportunity to get ...
(Date:2/28/2015)... WI (PRWEB) February 28, 2015 ... designation recognizes Mercy Harvard Hospital as stroke capable by ... be brought via ambulance to Mercy Harvard Hospital. , ... state to indicate their ability to treat stroke according ... designation allows ambulances transporting stroke patients to bypass hospitals ...
(Date:2/28/2015)... February 28, 2015 Memphis, TN: MedixSafe ... 2015, for a new security reader named Guardian ... reader is a new biometric scanner that significantly ... new features, the new biometric scanner provides fast ... administrators. , MedixSafe narcotics lockers with ...
(Date:2/28/2015)... California (PRWEB) February 28, 2015 ... supported and showcased emerging brand at Houston Texas ... in Las Vegas sending its executive delegates headed ... of Business Development and Training Randolph Clarito. , ... (IFA), was held last February 4-7 and featured ...
(Date:2/27/2015)... Santa Clara, CA (PRWEB) February 27, 2015 ... Integrated Passive Devices (IPD), has introduced miniature, wire bondable, ... Brightness and Power LED markets. The ESD88NP ... high transient currents away from sensitive LED and IC ... compared to Multilayer Varistors (MLV). All devices meet ...
Breaking Medicine News(10 mins):Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3
... and calcium have been the focus of much research since ... in 1997. Known as Dietary Reference Intakes, the values for ... nutrition and provide the scientific basis for the development of ... DRIs for these two nutrients are presented in a new ...
... found an effective two-part treatment for microtears in the hamstring: ... with "dry-needling," in which repeated needle punctures cause controlled internal ... presented today at the annual meeting of the Radiological Society ... blood where it is needed at the site of a ...
... "We blame kids for being fat, we blame kids for being ... not feeding their kids right," says Terrance Wade, the Canada Research ... of these things are not based on individual choices because your ... Wade is completing a five-year study funded by the Heart ...
... (November 29, 2010) Whitehead Institute researchers have shown ... (miR-125b) can independently cause leukemia and accelerate the disease,s ... edition of the Proceedings of the National Academy of ... but in humans and mice, can upregulation of a ...
... We Die: Reflections on Life,s Final Chapter, Sherwin B. Nuland, ... of end-of-life care today, progress in palliative care, and areas ... published in 1994 and won the National Book Award for ... by describing the physical deterioration that occurs with heart attack, ...
... an innovative use of cell phone records, researchers at UCLA, ... that women appear to avoid contact with their fathers during ... on these high-fertility days and they hang up with them ... a UCLA associate professor of communication in whose lab the ...
Cached Medicine News:Health News:Researchers use patient's own blood to treat hamstring injury 2Health News:Up to 8 percent of Canadian children suffer from elevated blood pressure 2Health News:Tiny RNA shown to cause multiple types of leukemia 2Health News:Tiny RNA shown to cause multiple types of leukemia 3Health News:Contact with dads drops when women ovulate 2Health News:Contact with dads drops when women ovulate 3Health News:Contact with dads drops when women ovulate 4
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
Inquire...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
Medicine Products: